References
- Coulman C. B., Annegers J. F., Kranz J. S. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983; 61: 403–7
- Ron E., Lunenfeld B., Menczer J., Blumstein T., Katz L. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987; 125: 780–90
- Brinton L. A., Melton L. J., III, Malkasian G. D., Jr., Bond A., Hoover R. Cancer risk after evaluation for infertility. Am J Epidemiol 1989; 129: 712–22
- Mosesson M., Koenig K. L., Shore R. E., Pasternack B. S. The influence of medical conditions associated with hormones on the risk of breast cancer. Int J Epidemiol 1993; 22: 1000–09
- Borkowski A., Puttaert V., Gyling M., Muquardt C., Bpdy J. J. Human chorionic gonadotropin-like substance in plasma of normal nonpregnant subjects and women with breast cancer. J Clin Endocrinol Metab 1984; 58: 1171–78
- Gardner W. U. Tumorogenesis in transplanted irradiated and nonirradiated ovaries. J Natl Cancer Inst 1961; 26: 829–53
- Stadel B. V. The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 1975; 123: 772–4
- Peterson C. M., Zimniski S. J. A long acting gonadotropin-releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG 1) heterotransplanted in the nude mouse. Obstet Gynecol 1990; 76: 264–67
- Willemsen W., Kruitwagen R., Bastiaans B., Hanselaar T., Rolland R. Ovarian stimulation and granulosa-cell tumor. Lancet 1993; 341: 986–8
- Gusberg S. B. Precursors of corpus carcinoma. Estrogens and adenomatous hyperplasia. AmJ Obstet Gynecol 1947; 53: 419–23
- Yee D., Paik S., Lebovic G. S., Marcus R. R., Favoni R. E. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989; 3: 509–17
- Pollak M. N., Huynh H. T., Lefevre S. P. Tamoxifen reduces serum insulin-like growth factor I (GF-1). Breast Cancer Res Treat 1992; 22: 91–100
- Olsson H., Borg A., Ferno M., Ranstan J., Sigurdsson H. HER-P/new and int-2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Nat Cancer Inst 1991; 83: 1483–87
- Fathalla M. F. Incessant ovulation - a factor in ovarian neoplasia?. Lancet 1971; ii: 163
- Atlas N., Mencher J. Massive hyperstimulation and borderline carcinoma of the ovary: a possible association. Acta Obstet Gynecol Scand 1982; 61: 261–3
- Carter M. E., Joyce D. N. Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for. in vitro fertilization: a case report. J In Vitro Fertil Embryo Transf 1987; 4: 126–8
- Brzezinski A. Management of menopause in women with breast cancer. Isr J Med Sci 1995; 31: 163–8
- Whittemore A. S. The risk of ovarian cancer after treatment for infertility. N Engl J Med 1994; 331: 805–6
- Harris R., Whittemore A. S., Itnyre I. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1204–11
- Cohen J., Forman R., Harlap S., Johannisson E., Lunenfeld B. IFFS Expert Group Report on the Whittemore study related to the risk of ovarian cancer associated with the use of infertility agents. Hum Reprod 1993; 8: 996–9
- Darder M. C. Fertility drugs and ovarian cancer: red alert or red herring - new information. Fertil Steril 1993; 60: 199
- Shushan A., Paltiel O., Iscovich J., Elchalal U., Peretz T., Schenker J. G. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 63: 13–18